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Abstract: Only recently has the perimenopause become recognized as a time when women 
are at risk for new onset and recurrence of major depression. Untreated depression at this time 
not only exacerbates the course of a depressive illness, but also puts women at increased risk 
for sleep disorders, cardiovascular disease, diabetes, and osteoporosis. Although antidepres-
sant medication is the mainstay of treatment, adjunctive therapy, especially with estrogen 
replacement, may be indicated in refractory cases, and may speed the onset of antidepressant 
action. Many, but not all, studies, report that progesterone antagonizes the beneficial effects of 
estrogen. Although some antidepressants improve vasomotor symptoms, in general they are not 
as effective as estrogen alone for relieving these symptoms. Estrogen alone, however, does not 
generally result in remission of major depression in most (but not all) studies, but may provide 
benefit to some women with less severe symptoms if administered in therapeutic ranges. The 
selective serotonin reuptake inhibitors (SSRIs) in addition to estrogen are usually more benefi-
cial in improving mood than SSRIs or estrogen treatment alone for major depression, whereas 
the selective norepinephrine and serotonin reuptake inhibitors do not require the addition of 
estrogen to exert their antidepressant effects in menopausal depression. In addition to attention 
to general health, hormonal status, and antidepressant treatment, the optimal management of 
perimenopausal depression also requires attention to the individual woman’s psychosocial and 
spiritual well being.
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Introduction
Kraepelin initially described involutional melancholia as a distinct clinical entity 
characterized by late onset, symptoms of fear, despondency, agitation, and hypochon-
driacal delusions, which formed the basis of the nomenclature in the second edition of 
the Diagnostic and Statistical Manual of Mental Disorders (DSM-II).1 A subsequent 
report discounted a syndrome of depression at menopause,2 which served as the 
basis for the removal of involutional melancholia from the DSM-III.3 Subsequent 
findings from the Cross-National Epidemiologic Study indicated an increase in new 
onset of depressive illness in the perimenopausal years (women aged 45–49). This 
later work is consistent with a developing database demonstrating an increased risk 
of major depressive episodes occurring in association with hormonal changes in the 
perimenopausal years.
The perimenopausal years refer to the time period when women’s menstrual cycles 
become irregular, generally between 45–49 years. According to the World Health Orga-
nization and the Stages of Reproductive Aging Workshop (STRAW),4 menopause is International Journal of Women’s Health 2010:2 144
Parry Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Cohen et al9 also examined the impact of the menopausal 
transition on depressive symptoms in 460 women without 
depressive histories aged between 36 and 45 years. During 
three years of follow-up, the menopausal group, especially 
women with hot flashes, was twice as likely to experience 
significant depressive symptoms as the premenopausal group. 
Major mood disorders occurred in 9.5% of premenopausal 
and 16.6% of perimenopausal women. These studies all used 
rigorous, standardized criteria for making psychiatric diag-
noses, and their results lend strong support to the hypothesis 
of increased vulnerability to an MDE occurring at the time 
of the menopausal transition.
Clinical phenomenology  
and epidemiology
Based on studies from menopause clinics (see review10), the 
most common symptom for which women seek treatment 
at menopause is mood change. Almost half of these women 
are clinically depressed and over a third experience their first 
episode of depression in the perimenopausal period. Two-
thirds of women in London and three-quarters of women in 
San Diego attending a university or community menopause 
clinic met criteria for recurrent MDD when evaluated by a 
psychiatric interview.11 Peri- compared with pre- or post-
menopausal women had a significant increase in depression 
rating scores. Mood and sleep disturbances were the most 
common symptoms in about 75% of women. Depressive 
episodes also are likely to recur in women with bipolar illness 
at menopause,12 and there is an increased number of suicides 
in women during this time period (45–64 years).13
Sleep
Systematic studies examining objective measures of sleep in 
carefully diagnosed patients in relation to endocrine markers 
of the menopause are limited, and the findings inconsistent.14 
Perceptions of sleep quality may differ in depressed, com-
pared with healthy menopausal women, and although women 
may complain of sleep disturbances more than men, they 
actually have better sleep quality as documented by objective 
recordings.15 Depressed menopausal women may also report 
increased severity of hot flashes during sleep, but in skin 
conductance studies of hot flashes, they actually have fewer 
and shorter hot flashes that disrupt sleep. Moreover, sleep dis-
turbances at menopause are related more to underlying sleep 
disorders (such as restless leg syndrome or apnea) or anxiety 
symptoms than to hot flashes. Hot flashes are more likely 
to disrupt sleep in the first, compared with the second, half 
of the night because of the suppressive effects of rapid eye 
defined as 12 months of amenorrhea following the final men-
strual cycle, the mean age of which is 51 years, when levels 
of follicle stimulating hormone (FSH) exceed 40 mIU/mL. 
The determination of menopausal status generally is made by 
clinical history rather than laboratory parameters, however, 
given the variability of individual hormonal levels.
Increased incidence of major 
depressive disorder at menopause
Many methodologic problems, especially of diagnostic and 
endocrine heterogeneity, characterize studies of menopausal 
mood disorders. More rigorous studies, which use standard-
ized, interview-based assessments of depression in endocrine-
defined phases of the menopausal transition, support an 
association between major depressive disorder (MDD) and 
menopause. In one such study from the National Institute of 
Mental Health (NIMH), Schmidt et al5 conducted a longi-
tudinal evaluation of the relationship between reproductive 
status and mood in perimenopausal women. The investigators 
used the structured clinical interview for DSM-IV (SCID)6 
for assessment of psychiatric diagnoses, and plasma levels 
of FSH obtained at 3–6 month intervals for an average of 
five years, to determine pre-, peri-, or postmenopausal status. 
For the 24 months surrounding women’s final menses, the 
risk for onset of depression was 14 times higher than for a 
31-year pre-menopausal time period. Women who developed 
a major depressive episode (MDE) during the perimeno-
pause were not distinguished from those who remained 
asymptomatic on the basis of symptom profiles, personal or 
family history of depression, duration of the perimenopause, 
vasomotor symptoms, life events, medical illness, use of 
medication, vitamins, minerals, or exercise. The timing of 
the depression, occurring in the context of recently elevated 
FSH levels, suggested that an endocrine mechanism related to 
the perimenopause (estradiol withdrawal and recent onset of 
prolonged hypogonadism) was involved in the pathophysiol-
ogy of perimenopausal depression. Other systematic studies 
are consistent with these findings. In an eight-year study, 
Freeman et al7 followed 231 women without depressive 
histories who were about to enter menopause. Using the 
Center for Epidemiological Studies of Depression (CES-D)8 
scale, they found that the probability of a high depression 
score (16) was four-fold greater during the menopausal 
transition than during the premenopausal phase. Entering 
menopause was linked to more than double the risk of being 
diagnosed with a depressive disorder and was associated 
with within-woman increases in FSH and luteinizing hor-
mone (LH), and greater variability of estradiol and FSH. International Journal of Women’s Health 2010:2 145
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movement (REM) sleep, which occurs predominantly in the 
second half of the night, on thermoregulation.16 Women with 
chronic insomnia, however, are at higher risk for developing 
depression. In subjective reports of sleep, lower estradiol lev-
els have been associated with poorer sleep quality, increased 
hot flashes, and increased anxiety and depressive symptoms. 
Estrogen treatment may improve sleep independent of its 
effect on hot flashes. In the Women’s Health Initiative (WHI), 
increased light exposure was associated with improved sleep 
and mood in older women.17
Past history
Studies of past psychiatric histories, including illness 
related to reproductive endocrine change, in women with 
menopausal depression support a depressive diathesis at 
menopause. Women who develop psychiatric symptoms in 
middle age are more likely to evidence psychiatric vulner-
ability, ie, a previous personal or family psychiatric history. 
A past history of depressive disorder occurs in over half of 
the women. In a five-year study of 2,565 women aged 45 
to 55,18 prior depression was the variable most predictive of 
subsequent depression.
Psychiatric symptoms at menopause are also related 
to previous depression associated with the reproductive 
cycle, such as premenstrual syndrome (PMS) or depres-
sion during pregnancy or the postpartum period. Stewart 
and Boydell19 found that psychologic distress during 
menopause was associated with a past history of PMS, 
depressive disorders treated with antidepressant medica-
tion, oral contraceptive-induced dysphoria, postpartum 
blues and MDD, suggesting an increased sensitivity to 
reproductive hormones in these psychiatrically vulnerable 
women. Freeman et al20 found that PMS was a predictor 
of menopausal symptoms and that women in the meno-
pausal transition were up to three times more likely to 
report depressive symptoms than premenopausal women. 
A history of depression was the strongest predictor of these 
changes.21 In interviews of 347 women 35–55 years of age 
in the Seattle Midlife Women’s Health Study, Woods and 
Mitchell22 found that a history of either premenstrual or 
postpartum affective symptoms distinguished women with 
consistently depressed mood.
Evidence supports the contention that the perimenopause 
increases susceptibility to depression, particularly, but not 
necessarily, among women with life-long susceptibility to 
MDD, including those whose MDEs were induced by repro-
ductive endocrine change (eg, during the premenstruum, 
pregnancy, or postpartum).
Risks of untreated depression
To determine the optimal treatment for perimenopausal 
  depression, clinicians must weigh the risks of untreated depres-
sion and the benefits of treatment. Untreated depression during 
the perimenopause exacerbates heart disease, diabetes, and 
osteoporosis.23–26 More specifically, with regard to cardiovascu-
lar (CV) disease, a higher prevalence of depressive disorders was 
associated with more severe atherosclerosis;27 recurrent depres-
sive, but not anxiety, disorders were associated with a two-fold 
increase in the risk of carotid atherosclerosis in middle-aged 
women, however, lifetime history of a single depressive episode 
was not associated with increased risk of plaque, suggesting 
that prevention of recurrent depressive episodes may prevent 
further progression of atherosclerosis; patients with depressive 
symptoms have lower health benefits (lower functioning) after 
coronary artery bypass surgery;28 symptoms of depression are 
significantly related to increased risk of CV events in women 
suspected of myocardial ischemia,29 to death from CV disease 
and, based on the findings from the WHI observational study, 
to all-cause mortality, even after controlling for established CV 
disease risk factors.30 As Eaton reviews,31 major depression 
increases the risk of first heart attack (odds ratio [OR] 3.9), 
stroke (OR 2.7) and diabetes (OR 2.23). In addition to depression 
being associated with increased bone loss32–35 and fracture,36 it 
is also associated with other menopausal symptoms of urinary 
incontinence37 and hot flashes.38
Contributing endocrine 
mechanisms
To provide optimal treatment for perimenopausal depres-
sion, it is worthwhile to examine the possible contributing 
endocrine mechanisms. Harlow et al39 found that women 
with a history of depression were at increased risk for an 
earlier perimenopausal transition with higher FSH and LH 
levels and lower estradiol (E2) levels. In a study examining 
hormonal predictors of depression in women in transition to 
the menopause, Freeman et al21 found that rapidly increasing 
FSH levels were associated with a decreased likelihood of 
depressive symptoms, whereas increasing estradiol levels 
were associated with more depressive symptoms. In a later 
study, Freeman et al7 observed that in women without a 
history of depression who were undergoing the menopausal 
transition, increased depression ratings on the Center for 
Epidemiological Studies of Depression scale (CES-D) 
were associated with increased levels of FSH and LH and 
increased variability of estradiol, FSH and LH. Other than 
lower morning dehydroepiandrosterone (DHEA) and its International Journal of Women’s Health 2010:2 146
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sulfated metabolite DHEA-S, Schmidt et al5,40 did not find 
associations between basal plasma hormone levels (FSH, 
LH, E2, estrone-E1, total-T or free testosterone-FT, E2/LH 
ratio, cortisol) in women with first onset of major or minor 
depression during the perimenopause and matched healthy 
comparison women. However, women with hot flashes who 
were older, regardless of the presence of depression, had 
significantly higher plasma levels of FT, LH, and FSH, and 
lower E2/LH ratios.40 Depressed mood was also not related to 
hormonal measures of urinary estrone glucuronide, FSH, or 
testosterone in the Seattle Midlife Women’s Health study.41 
Increased FSH levels and older age can be associated with 
a poor response to antidepressant treatment in post- versus 
premenopausal women.42 Earlier age at menopause in women 
with lower educational levels increased their risk of depres-
sion, but long-term oral contraceptive use (10 years) was 
protective against depression.43 Earlier bilateral oophorec-
tomy before the onset of menopause is associated with an 
increased risk of depressive symptoms.44
It may be the alteration of sleep-endocrine relationships 
that is associated with major depression during the meno-
pause transition. Antonijevic et al45 found increased nocturnal 
cortisol and alterations in FSH secretion in relation to slow 
wave sleep in postmenopausal depressed women compared 
with postmenopausal controls. It also may be that fluctuat-
ing, rather than absolute, hormonal levels are associated with 
depressive symptoms, emphasizing the need for prospec-
tive studies. For example, Ryan et al46 in their prospective 
study of the association between endogenous hormones and 
depressive symptoms in postmenopausal women found no 
significant associations between depressive symptoms and 
absolute levels of sex hormone-binding globulin, testoster-
one, free androgen index, estradiol, free estradiol, or FSH, 
but did find that women with a decline in total serum estradiol 
or, to a lesser extent, large increases in FSH over a two-year 
period had up to a three-fold increased risk of depressive 
symptoms. In Freeman’s 10-year follow-up study,38 within-
woman increases in FSH were associated with the onset of 
depressed mood, which preceded the development of hot 
flashes, associated with increased FSH levels, decreased 
inhibin levels, and variability of estradiol levels. A decrease in 
FSH was correlated with improved scores in verbal memory 
in perimenopausal women who responded to estrogen aug-
mentation of antidepressant medication.47 In postmenopausal 
depression, improved antidepressant response to SSRIs was 
inversely correlated with basal levels of LH.48 The effects may 
be mediated by altered neurotransmitter, neuroendocrine, 
circadian rhythm, or EEG alpha/beta function.49,50
Thus, no specific absolute levels of hormonal profiles 
that would guide treatment recommendations consistently 
characterize women at risk for developing perimenopausal 
depression. Rather, it appears to be the fluctuating levels of 
hormones during the menopausal transition, and perhaps 
their effects on other endocrine, neurotransmitter, or cir-
cadian systems, that contribute to women’s vulnerability 
for the development of depressive symptoms during the 
perimenopause.
Treatment
The studies examining the effects of hormone replacement 
on mood in menopausal depressed patients vary depending 
on the diagnosis (eg, MDD), their menopausal status (includ-
ing the presence of hot flashes), the dose and preparation of 
estrogen and progesterone replacement, and the duration of 
treatment (see review51).
In initial studies52 not confined to menopausal women, 
25 µg of ethinyl estradiol added to imipramine was superior 
to 50 µg of ethinyl estradiol plus imipramine or imipramine 
alone in 30 women with primary depression. The higher dos-
age of estrogen, although associated with less insomnia, was 
also associated with significant side effects (lethargy, hypo-
tension, tremor, depersonalization). These findings suggest 
there may be a therapeutic window for estrogen treatment; 
if endogenous levels are already high, additional estrogen 
supplementation may lead to toxic reactions.
In a six-week nonrandomized trial53 in primarily post-
menopausal women (60 years) with unipolar depression, 
72 women who received fluoxetine (20 mg/day) and estro-
gen replacement therapy (ERT, primarily Premarin®) had a 
greater improvement in depression ratings than 286 women 
on ERT alone (40% versus 17%, respectively). Fluoxetine-
treated patients not on ERT did not show benefit greater than 
placebo. Thus, estrogen enhanced the efficacy of fluoxetine 
treatment. Ping et al54 also found that hormone replacement 
therapy (HRT) with 0.625 mg of conjugated estrogen and 
5 mg of progesterone combined with 20 mg fluoxetine for 
two months was more effective in reducing symptoms than 
HRT alone in 123 women with menopausal depression. In 
a study of sertraline (50–150 mg),55 women over 60 years 
receiving ERT (without progesterone) had greater global 
improvement, better quality of life, less anxiety, and modest 
improvements in cognitive functioning than women receiving 
sertraline but not ERT.
In contrast, in our laboratory, we found that although oral 
(1–2 mg Estrace®) or transdermal (0.1–0.2 mg Estraderm®) 
17-beta estradiol enhanced the antidepressant effects of International Journal of Women’s Health 2010:2 147
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fluoxetine (10–40 mg) in an eight-week pilot study of women 
with peri- or postmenopausal MDD,56 in a follow-up random-
ized clinical trial, the combination of antidepressant (AD) 
plus estrogen was not superior to AD alone; in fact, patients 
receiving AD plus estrogen showed smaller (nonsignificant) 
reductions in interview-based depression ratings than those 
patients receiving AD alone,51 a finding supported by other 
studies.57 Estrogen treatment alone did not significantly 
reduce symptoms of MDD. Estrogen treatment, however, 
may accelerate the antidepressant response as shown by 
Rasgon et al58 with respect to sertraline.
In an open-label pilot study, Freeman et al59 found that 
the SSRI escitalopram alone for eight weeks significantly 
improved psychologic, vasomotor, and somatic symptoms. 
Escitalopram was more efficacious for the treatment of 
depression than ethinyl estradiol and norethindrone acetate 
in another study.60 Soares et al61 found that in peri- and post-
menopausal women with depressive disorders who failed to 
show remission of depression after four weeks of estrogen 
therapy, derived benefit from adjunctive treatment for eight 
weeks with 20–60 mg of citalopram.
In refractory depressed patients, however, estrogen may 
enhance the efficacy of antidepressant medication.62,63 In 
small studies64,65 in which the investigators examined the 
effect of gradually increasing doses of Premarin or placebo 
for a month in three premenopausal and eight postmenopausal 
women with refractory depression, although there was no 
overall improvement in depression scores with estrogen 
or placebo, one bipolar patient whose depression had been 
treatment-resistant for two years, developed mania that began 
nine days after estrogen treatment. Another patient showed 
striking improvement after one week of estrogen treatment 
and was no longer depressed after two weeks, a remission 
that lasted three months. Thus, occasionally patients do 
appear to have therapeutic responses to estrogen. In women 
with treatment-resistant MDD, estrogen supplementation in 
replacement dosages may have important additive effects to 
AD medication, to which menopausal women may otherwise 
be refractory. Depending on the dosage in relation to pro-
gesterone, estrogen also may induce66 or stabilize12,67 rapid 
mood cycling in some patients.
In chronic depression, some studies suggested that in 
menopausal women not on estrogen replacement therapy, 
efficacy and tolerability were better with tricyclic antide-
pressant (TCA) medication. To achieve the same degree 
of efficacy and tolerability with the SSRIs in menopausal 
depressed women, estrogen replacement needed to be added, 
presumably to downregulate postsynaptic serotonin receptors 
(findings based on the animal literature). Additional work, 
however, supported this differential effect of TCA versus 
SSRI medication in pre-, but not postmenopausal women. In 
a further analysis of women over 50 years, although hormone 
replacement therapy (HRT) enhanced the effect of SSRIs and 
placebo response, venlafaxine, perhaps because of its dual 
inhibition of serotonin and norepinephrine receptors, did not 
differentially affect outcome as a function of the addition 
of HRT (see review68), as did mirtazapine in an open trial.69 
Venlafaxine alone may improve depressive and vasomotor 
symptoms in women with perimenopausal depression.70 
Methyltestosterone further augmented the effects of venla-
faxine, but was associated with a high dropout rate.71 In an 
open trial of the serotonin-norepinephrine reuptake inhibitor 
duloxetine, Joffe et al72 found that 60–120 mg reduced symp-
toms for depression, vasomotor symptoms, sleep, anxiety and 
pain after eight weeks of treatment.
Other studies suggest that estrogen treatment alone or 
combined with progestins may reduce depressive symptoms 
in MDD.63,73–77 Klaiber et al73 found that three months of treat-
ment with oral conjugated estrogen 5–25 mg compared with 
placebo significantly reduced Hamilton ratings of depression 
for severe persistent depressions in pre- and postmenopausal 
inpatient women unresponsive to other medications which had 
been withdrawn for 2–3 weeks, psychotherapy, or electrocon-
vulsive therapy. Treatment, however, resulted in improvement, 
but not in remission, of symptoms and was not uniform within 
the group, with women having less chronic illness responding 
more favorably. A shorter length of illness, but not meno-
pausal status or age, was significantly related to the amount 
of improvement. The depressed women had elevated levels 
of monoamine oxidase (MAO) activity, which were reduced 
with estrogen therapy, but not placebo. The magnitude of 
improvement did not correlate with MAO levels, however. In a 
study78 of postmenopausal hysterectomized women, those who 
received conjugated equine estrogens 0.625 mg/day for six 
months had a significant decrease in depressive mood symp-
toms as measured by the Hamilton Rating Scale compared with 
women who received no treatment. In a randomized, controlled 
trial of eight weeks’ treatment with 1 mg/day estradiol patch or 
placebo, Morrison et al79 found no clinically significant anti-
depressant effect of estradiol on mild to moderate depression 
in postmenopausal women. Although no significant increase 
in depressive symptoms was found with use of medroxypro-
gesterone 10 mg/day for two weeks, positive affect decreased 
slightly when combined with estradiol. However, Cagnacci 
et al74 found that estrogens plus progestins reduced depression 
and anxiety in climacteric women and that progestins did not International Journal of Women’s Health 2010:2 148
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counteract the beneficial effects of estrogen. In contrast, an 
earlier cross-sectional study by Palinkas and Barrett-Connor80 
in women 50 years and older living in California found that 
women using noncontraceptive estrogen had significantly 
higher Beck Depression Ratings (score  13) than untreated 
women of the same age. After 60 years, depressive symptoms 
decreased. The authors postulated that more symptomatic 
women sought treatment.
Overall, in the studies that demonstrated efficacy, 17-beta 
estradiol, the most active form of estrogen to cross the blood-
brain barrier, was used for at least four weeks. Soares et al76 
found that the transdermal patch of 100 µg of 17-β-estradiol 
for 12 weeks was efficacious compared with placebo in women 
with perimenopausal depressive disorders, and that the anti-
depressant effects, but not necessarily the benefit on somatic 
symptoms, was maintained four weeks after withdrawal. 
Estrogen levels, however, did not correlate with clinical 
response. Some depressed women had a satisfactory response, 
despite low levels of estrogen, raising the question of whether 
estrogen deficiency is really necessary to elicit a therapeutic 
response.81 In a small open-label study, Cohen et al77 found 
that a four-week course of transdermal estrogen (100 µg/day) 
benefited both peri- and postmenopausal women. In the studies 
that used progesterone replacement in addition to estrogen, the 
progesterone tended to decrease the beneficial effects of estro-
gen, and in some but not all patients, exacerbated depressive 
symptoms, especially in those women who had had previous 
episodes of depression or who developed negative affect from 
progestin-containing contraceptives.
In non-depressed clinical samples, investigators in WHI82 
failed to find a significant effect of estrogen plus progestin 
on depressive symptom scores after three years. In the Heart 
and Estrogen/Progestin Replacement Study (HERS),83 only 
women with hot flashes who were assigned to hormone 
therapy benefited by having better mental health and fewer 
depressive symptoms. Women without hot flashes assigned to 
hormone therapy had greater declines in physical functions, 
energy, and fatigue. In a study of 48 nondepressed women 
aged 47–57 years,84 estrogen treatment (Premarin) enhanced 
mood, but women given progesterone (Provera®) showed 
more negative affect, unless counteracted by higher dosages 
of estrogen. In nonclinically depressed women who had pre-
viously undergone hysterectomy and bilateral oophorectomy, 
three months of treatment with ethinyl estradiol versus pla-
cebo improved depression, anxiety, irritability, and insomnia 
as assessed by the Hamilton Depression Rating Scale. Treat-
ment with a progestin showed less favorable changes, and 
the effects were diminished by three months.85
For hot flashes, randomized controlled trials of SSRIs, 
selective norepinephrine reuptake inhibitors (SNRIs), gabap-
entin and clonidine did provide evidence of efficacy, although 
the effect was less than that with estrogen therapy (see 
review86). Venlafaxine and paroxetine have been studied 
more extensively than any of the other antidepressants and 
are more consistent in effectively reducing the frequency 
and severity of hot flashes. Desvenlafaxine, sertraline, 
fluoxetine, and citalopram should be considered second- or 
third-line options. Duloxetine, escitalopram, fluvoxamine, 
and mirtazapine should be reserved as last-line therapy 
for hot flashes.87 Schmidt et al75 using 0.05 mg/day of the 
17β-estradiol patch for three weeks reduced depressive symp-
toms in perimenopausal women, irrespective of the presence 
of hot flashes or the duration of treatment. Treatment of hot 
flashes with hormone therapy is cost-effective in the US.88
Regarding the risks of hormonal therapies, although 
the WHI initially reported an increased incidence of breast 
cancer or cardiovascular disease in 4–5/10,000 women over 
five years,89 the majority of the women in this study were 
older (60–79 years) with higher body mass indices.90 More 
recent evidence suggests that use of HRT within 10 years of 
the onset of menopause (between 50–59 years) is associated 
with reduced risk of cardiovascular disease.91 According to 
the North American Menopause Society, it is reasonable to 
use hormonal therapies to treat menopausal symptoms in the 
absence of related risk factors such as cardiovascular disease 
or breast cancer, repeatedly presenting the option of stopping 
or reducing the dose.92 The decision to use HRT should be 
done in consultation with the individual woman’s physician, 
weighing her particular risks and benefits.
Regarding alternative treatments, St John’s wort and black 
cohosh appear to be the most useful in alleviating mood and 
anxiety changes (not disorders) during menopause.93
Conclusion
Perimenopausal women in particular are at risk for new onset 
and recurrence of MDEs. Women with previous histories of 
PMS or postpartum depression are at increased risk. The 
symptoms may present with features of melancholia, agita-
tion, somatic symptoms, or sleep disturbances. The increase 
in MDEs occurring at this time has been found to be linked 
to hormonal changes of the menopausal transition, namely 
increased FSH levels, rather than to social or environmental 
triggers, although changes in valued lifestyle factors asso-
ciated with, for example, motherhood, family, fertility, or 
physical rigor and attractiveness, may precipitate depressive 
mood changes in predisposed or vulnerable women. Women International Journal of Women’s Health 2010:2 149
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who worry about others are at increased risk for developing 
clinical depression. Other women may value the new-found 
independence that these lifestyle changes incur.
Untreated depression may exacerbate heart disease, 
diabetes, and osteoporosis, as well as contributing to an 
increased risk for suicide and to a more debilitating course 
of the depression that is more refractory to intervention.
Estrogen treatment alone may reduce hot flashes and 
improve sleep, but has not been shown consistently to be effi-
cacious as monotherapy in MDD. In some women refractory 
to particularly SSRI AD medication, addition of estrogen may 
enhance efficacy, reduce response time, and obviate the need 
for increasing the AD dose with its attendant side effects. If a 
woman cannot tolerate estrogen replacement, then antidepres-
sant medication other than an SSRI (eg, a TCA such as nortrip-
tyline or desipramine; or an SNRI or dual-receptor reuptake 
inhibitor, eg, mirtazapine, venlafaxine, or duloxetine) should be 
tried. For vasomotor symptoms in women who cannot tolerate 
estrogen therapy, paroxetine or venlafaxine are the antidepres-
sants which have the most evidence for efficacy and tolerability. 
Progesterone may increase depressive symptoms in women 
with a previous history of depression. Estrogen or progesterone 
hormone replacement should be given in consultation with a 
gynecologist or primary care physician who can monitor the 
development of any untoward side effects on the uterus, breast, 
or cardiovascular system. Many women may opt to have annual 
endometrial biopsies as an outpatient procedure.
The North American Menopause Society consensus 
statement indicates that it is reasonable to use HRT in 
symptomatic women in the perimenopause and, as recent 
evidence suggests, up to 10 years after menopause, given that 
the benefits may outweigh the risks. The most active form 
of estrogen, 17-beta estradiol, is the most likely to cross the 
blood-brain barrier and exerts potential beneficial effects on 
mood, sleep, cognitive function, and vasomotor symptoms.
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